DONAL MCLORNAN (LONDON)
CHRONIC MYELOMONOCYTIC LEUKAEMIA (CMML)
Chronic Myelomonocytic Leukaemia (CMML) is a myelodysplastic/myeloproliferative
neoplasm with a male predominance and is frequently a heterogeneous disorder with regard
to molecular landscape, clinical phenotype and disease trajectory 1–3. Over the last decade,
marked advances have been made in understanding the mutational landscape of CMML but
therapeutic management has historically been challenging. Therapeutic options when
required depend on phenotype, age and performance status ranging from anaemia
management, hypomethylating agents (HMA), intensive chemotherapy in suitable individuals
(frequently used if considering allogeneic haematopoietic cell transplant (allo-HCT)), allo-HCT
or more experimental approaches include JAK inhibitors, BH3 mimetics, spliceosome targeted
agents and polo like kinase (PLK) inhibitors amongst others3,4. In this case, I will discuss a 67-
year male with proliferative CMML and focus on utilisation of molecular prognostication,
potential therapeutic options, decision making for pre-allo-HCT therapy (or not?) and
optimisation of post allo-HCT outcome.
References:
1. Solary E, Itzykson R. How I treat chronic myelomonocytic leukemia. Blood 2017; 130: 126–36.
2. Patnaik MM, Lasho TL. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm
overlap syndromes. Hematology Am Soc Hematol Educ Program 2020; 2020: 450–9.
3. Patnaik MM, Lasho T. Myelodysplastic syndrome/myeloproliferative neoplasm overlap
syndromes: a focused review. Hematology Am Soc Hematol Educ Program 2020; 2020: 460–4.
4. Liu HD, Ahn KW, Hu Z-H, et al. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic
Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation 2017; 23: 767–75.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES